Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer

To observe and evaluate the neoadjuvant treatment of Envafolimab combined with Fruquintinib and chemotherapy for locally advanced gastric/gastroesophageal junction carcinoma

Trial Details

NCT ID
NCT06791083
Phase
PHASE2
Sponsor
First Affiliated Hospital of Fujian Medical University
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Envafolimab
  • Fruquintinib
Locations (sample)
  • Fuzhou, Fujian, China|26.06139,119.30611

Key Eligibility Criteria

  • Have fully understood the study and voluntarily signed the informed consent;
  • Aged 18-75 years (including 18 and 75 years);
  • Pathologically confirmed or potentially resectable locally advanced gastric/gastroesophageal junction adenocarcinoma (cT2-T4b, N+M0);
  • If bone metastasis is suspected, a bone scan should be performed. If peritoneal metastasis is suspected, abdominal examination should be performed …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →